Potential role of PRKCSH in lung cancer: bioinformatics analysis and a case study of Nano ZnO

Ridan Lei, Meiling Zhou, Shusheng Zhang, Jinhua Luo, Can Qu, Yin Wang, Peiyu Guo, Ruixue Huang

Nanoscale · 2022 · 16 citations · 46 references

Concepts

Abstract

< 0.001) in lung cancer tissues. We further found that PRKCSH deficiency promoted G2/M arrest in response to zinc oxide nanoparticle (Nano ZnO) treatment in A549 cells. With regard to the mechanism, PRKCSH deficiency may induce STAT6 translocation to the nucleus to activate p53 expression through binding to the p53 promoter region from -365 bp to +126 bp. Eventually, activated p53 contributed to Nano-ZnO-induced G2/M arrest in lung cancer cells. Taken together, our data provide new insights into immunotherapy target choices and the prognostic value of PRKCSH. Since the G2/M cell cycle checkpoint is crucial for lung cancer prognosis, targeting PRKCSH expression to suppress the activation of the STAT6/p53 pathway is a potential therapeutic strategy for managing lung cancer.

References

46